Disclaimer: This article is intended solely for informational and educational purposes only. It does not constitute medical advice.
Itching (pruritus) is a common and significant side effect of neuraxial opioid administration. Despite decades of clinical investigation, it remains difficult to manage after anesthesia and surgery. Reported incidence ranges widely from 30% to 100%, with parturients undergoing cesarean delivery consistently identified as the most susceptible population, likely reflecting an interaction between estrogen and opioid receptors [1,2]. Following major orthopedic and urologic surgery, incidence tends to be lower, typically between 30% and 68% [1,3]. Intrathecal fentanyl alone has been associated with pruritus in 67-100% of patients, while intrathecal morphine carries rates of roughly 60–85% [2,4].
The pathophysiology of pruritus is multifactorial. Peripheral mechanisms involve opioid-induced mast cell degranulation and histamine release, though antihistamines are frequently clinically ineffective, suggesting histamine is not the dominant driver [2]. Central mechanisms appear more important, centering on μ-opioid receptor activation in the medullary dorsal horn and the spinal nucleus of the trigeminal nerve, an area rich in opioid and serotonin type-3 (5-HT3) receptors that has been proposed as an “itch center” [1,2].
At the molecular level, morphine-induced activation of the μ-opioid receptor isoform MOR1D and its heterodimerization with the gastrin-releasing peptide receptor (GRPR) appears to disinhibit spinal pruriceptive neurons independent of analgesic pathways, while κ-opioid receptor agonism and endogenous dynorphin appear to suppress this itch signal [2]. This dissociation between analgesic and pruritic pathways helps explain why opioid agonist-antagonists can relieve itch without substantially compromising pain control.
Research on preventing itching (pruritus) after anesthesia has found benefits with three drug classes: 5-HT3 receptor antagonists, dopamine D2 antagonists, and mixed μ-opioid agonist-antagonists or κ-agonists. Ondansetron, given prophylactically before neuraxial opioid administration, has shown a reduction in intrathecal fentanyl-induced pruritus from 68% to 39% in one randomized controlled trial [5], though some studies have failed to replicate this effect. A review found that 5-HT3 antagonists were reliably effective only when given before, rather than after, morphine administration [3]. Dopamine antagonists such droperidol and alizapride have shown a fairly consistent prophylactic effect regardless of timing, with average incidence reductions of roughly 39–45%, though droperidol carries a QT-prolongation risk that limits its use [3].
Opioid agonist-antagonists have also shown positive results in the prevention of itching after anesthesia. A single 15-mg intravenous dose of pentazocine reduced pruritus incidence from 77% to 53% after cesarean delivery with intrathecal opioids and prolonged the time to onset [4]. Nalbuphine has shown average incidence reductions of roughly 63% when used prophylactically and remains the most consistently effective agent for established pruritus [3]. Butorphanol has also demonstrated efficacy both epidurally and intravenously [2]. Full μ-opioid antagonists such as naloxone and naltrexone are effective but carry a meaningful risk of reversing analgesia, limiting their outpatient use. Other agents, including gabapentin, subhypnotic propofol, and NSAIDs, have shown inconsistent or modest benefit and are not considered first-line [2,3].
Minimizing opioid dose while using multimodal analgesia remains the most reliable strategy for reducing risk of postoperative pruritus. When pharmacologic prophylaxis is desired, 5-HT3 antagonists given before neuraxial opioid dosing, dopamine antagonists, or low-dose opioid agonist-antagonists are reasonable choices, while nalbuphine remains the preferred treatment once pruritus is established.
References
- Szarvas, S., Harmon, D. & Murphy, D. Neuraxial opioid-induced pruritus: a review. J. Clin. Anesth. 15, 234–239 (2003). https://doi.org/10.1016/S0952-8180(03)00501-9
- Okutani, H., Lo Vecchio, S. & Arendt-Nielsen, L. Mechanisms and treatment of opioid-induced pruritus: peripheral and central pathways. Eur. J. Pain 28, 214–230 (2024). https://doi.org/10.1002/ejp.2180
- Becker, L. M., Teunissen, A. J. W. & Koopman, J. S. H. A. Prevention and treatment of neuraxial morphine-induced pruritus: a scoping review. J. Pain Res. 15, 1633–1645 (2022). https://doi.org/10.2147/JPR.S361225
- Hirabayashi, M., Doi, K., Imamachi, N., Kishimoto, T. & Saito, Y. Prophylactic pentazocine reduces the incidence of pruritus after cesarean delivery under spinal anesthesia with opioids: a prospective randomized clinical trial. Anesth. Analg. XXX, 1–5 (2017). https://doi.org/10.1213/ANE.0000000000002060
- Gürkan, Y. & Toker, K. Prophylactic ondansetron reduces the incidence of intrathecal fentanyl-induced pruritus. Anesth. Analg. 95, 1763–1766 (2002). https://doi.org/10.1213/01.ANE.0000033097.30674.02
